Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.







29.05.2022, 3749 Zeichen

Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics, reported today its financial results for the first quarter of 2022. Revenues increased to Euro 2.4 m by 8.8 % compared to the previous year (Q1 2021: € 2.2 m) with continued strong demand for the virus blocker Carragelose. In addition to COVID-19, regular colds and flus, which are spreading again after hygiene measures have been reduced, support increased sales of the virus blocker. Revenues came in also from Solv4U, which was launched in Q4 2021 to address solubility and bioavailability issues in technology partnerships for biopharma companies. With Euro 1.6 mn, Marinomed reported lower R&D expenses compared to the previous year (Q1 2021: Euro 2.2). This is mainly due to currently reduced clinical research activities as Marinomed completed several clinical trials in 2021 and is now in preparations for shifting its focus more towards the development of Rx medicines. Marinomed plans to take full advantage of its powerful Marinosolv technology as well as of iota-carrageenan to treat diseases with limited or no treatment options in immunology and virology. Clinical development for Rx medicines is more time consuming and, therefore, Marinomed expects lower R&D expenses for the current year and a subsequent increase for both clinical trials and the expansion of the Marinosolv pipeline. The operating result (EBIT) was -1,2 mn and improved by 28.8 % compared to the previous year (Q1 2021: Euro -1.7 mn). This can be attributed to the increased revenues but mainly to lower R&D expenditures. Net loss for the period was Euro 1.8 mn compared to Euro 2.1 mn in Q1 2021. This is in line with the company’s business plan.Cash and cash equivalents amounted to Euro 11.7 m at the end of the first quarter 2022 (31 Dec. 2021: Euro 5.8 m). “We are proud to report again a record-breaking quarter in a more than challenging geopolitical environment. Our Carragelose products continue their strong growth path and our partners around the globe are prepared to stock up as needed. SARS-CoV-2 is becoming endemic and common respiratory viruses have a comeback so that the need for broad-band virus blocking products will continue. The strength of our products resulted in the new partnership with Hanmi Pharmaceutical Co., Ltd., one of the largest South Korean pharmaceutical companies,” said Andreas Grassauer, Marinomed’s CEO. 
Marinomed Biotech: weekly performance: 1.87%

Fabasoft: Fabasoft Approve, the product for managing technical data and documents launched by software manufacturer Fabasoft and employed successfully in industry since 2019, became an independent company on April 27, 2022. Entrepreneur Andreas Dangl will assume the management of the new digitalization services company. As a defining leader in the Fabasoft Group, Dangl was responsible for the development of Fabasoft Cloud technology and was both the idea generator as well as the principal architect of software products including Fabasoft Approve. He is now pooling his expertise in the corporation based in Linz (Austria) with the express intention of re-imagining the digital world in mechanical and plant engineering and rendering it simpler to navigate. "Fabasoft Approve GmbH provides the perfect framework for meeting the needs of our industrial customers in an even more focused way. We have exciting times ahead of us, in which my team and I, together with our clients, will tap the innovative potential of this very dynamic and exciting field even more fully," reveals Andreas Dangl, Managing Director of Fabasoft Approve GmbH.
Fabasoft: weekly performance: -2.96%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (23/05/2022)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Plausch S2/58: CPI ist nicht CPI, Ärger über Leute von Michael Ludwig (leider no Deep Fake)


 

Bildnachweis

1. Fabasoft Geschäftsbericht 2020/2021 - https://boerse-social.com/companyreports/2021/214507/fabasoft_geschaftsbericht_20202021



Aktien auf dem Radar:Flughafen Wien, voestalpine, Mayr-Melnhof, Warimpex, Amag, Immofinanz, AMS, EVN, AT&S, FACC, Palfinger, Rosenbauer, Oberbank AG Stamm, BKS Bank Stamm, Addiko Bank, S Immo, Deutsche Boerse, Symrise, Beiersdorf, Sartorius, Qiagen, Siemens Healthineers, adidas, Fresenius Medical Care, Fresenius, HelloFresh, E.ON , Rocket Internet, Ahlers, Frequentis, Wienerberger.


Random Partner

KTM
Die KTM Industries-Gruppe ist eine europäische Fahrzeug-Gruppe mit dem strategischen Fokus auf das globale Sportmotorradsegment und den automotiven high-tech Komponentenbereich. Mit ihren weltweit bekannten Marken KTM, Husqvarna Motorcycles, WP und Pankl zählt sie in ihren Segmenten jeweils zu den Technologie- und Marktführern.

>> Besuchen Sie 62 weitere Partner auf boerse-social.com/partner



Meistgelesen
>> mehr


PIR-Zeichnungsprodukte
AT0000A2TJM2
AT0000A2T4E5
AT0000A2GHJ9

Börse Social Club Board
>> mehr
    Star der Stunde: Immofinanz 0.55%, Rutsch der Stunde: voestalpine -1.59%
    wikifolio-Trades Austro-Aktien 16-17: SBO(1), AT&S(1)
    Star der Stunde: Porr 1.7%, Rutsch der Stunde: Semperit -1.2%
    wikifolio-Trades Austro-Aktien 15-16: Immofinanz(1)
    BSN Vola-Event MTU Aero Engines
    BSN MA-Event Mayr-Melnhof
    Österreich-Depots: Dividende von Porr eingelangt (Depot Kommentar)
    Star der Stunde: Rosenbauer 0.84%, Rutsch der Stunde: FACC -0.98%
    wikifolio-Trades Austro-Aktien 14-15: Strabag(1)